Draxis regulatory update

The FDA granted marketing approval for Anipryl (l-selegiline) to treat canine Cushing's disease. DRAXF also

Read the full 155 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE